FDA approves MACE label claim for Lilly’s TrulicityEli Lilly has firmed up the label for its type 2 diabetes therapy Trulicity with FDA approval for Share XFDA approves MACE label claim for Lilly’s Trulicityhttps://pharmaphorum.com/news/fda-approves-mace-label-claim-for-lillys-trulicity/
Ozempic acceleration buoys Novo Nordisk, and threatens LillySolid growth for Novo Nordisk’s weekly GLP-1 agonist Ozempic in the fourth quarter helped the Danish drugmaker beat Share XOzempic acceleration buoys Novo Nordisk, and threatens Lillyhttps://pharmaphorum.com/news/ozempic-acceleration-buoys-novo-nordisk-and-threatens-lilly/
Novo Nordisk nears EU okay for oral GLP-1 drug Rybelsus after CHMP nodThe EMA’s main advisory committee has backed approval of Novo Nordisk’s oral GLP-1 agonist Rybelsus, a key pipeline Share XNovo Nordisk nears EU okay for oral GLP-1 drug Rybelsus after CHMP nodhttps://pharmaphorum.com/news/novo-nordisk-nears-eu-okay-for-oral-semaglutide-after-chmp-nod/
Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challengeEli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but Share XLilly’s diabetes med Trulicity shrugs off Novo Nordisk challengehttps://pharmaphorum.com/news/lillys-diabetes-med-trulicity-shrugs-off-novo-nordisk-challenge/
